Predictors of atrial fibrillation recurrence after atrial fibrillation ablation with cryoballoon by Evranos, Banu et al.
ORIGINAL ARTICLE
Cardiology Journal 
2013, Vol. 20, No. 3, pp. 294–303
DOI: 10.5603/CJ.2013.0075
Copyright © 2013 Via Medica
ISSN 1897–5593
294 www.cardiologyjournal.org
Address for correspondence: Banu Evranos, MD, Hacettepe University Cardiology Department, Altındağ,  
06100 Ankara, Turkey, tel: 05337379539, e-mail: banuevranos@yahoo.com
Received: 02.02.2013 Accepted: 06.03.2013
Predictors of atrial fibrillation recurrence after 
atrial fibrillation ablation with cryoballoon
Banu Evranos, Kudret Aytemir, Ali Oto, Sercan Okutucu, Uğur Karakulak,  
Levent Şahiner, Barış Kaya, Giray Kabakçı
Hacettepe University Department of Cardiology, Ankara, Turkey
Abstract
Background: Catheter ablation of atrial fibrillation is recommended for patients with symp-
tomatic paroxysmal atrial fibrillation (PAF) despite anti-arrhythmic drugs (AADs). Radiofre-
quency ablation is widely accepted as an effective treatment for PAF. Cryoenergy by cryoballoon 
technique is an alternative to radiofrequency (RF) ablation. Cryoballoon ablation is safe, and 
has a similar success rate in comparison to RF ablation. AF recurrence with cryoballoon ab-
lation is roughly 30%. The aim of this study is to determine the predictors of AF recurrence 
after cryoballoon ablation. 
Methods and Results: Sixty one patients with symptomatic PAF despite AADs without 
structural heart disease were included. Cryoballoon ablation was performed in 60 patients 
(36 males, mean age: 54.6 ± 10.7, mean left atrium size: 3.74 ± 0.39 mm). Transthoracic 
echocardiography including tissue Doppler imaging was performed in all subjects during sinus 
rhythm at baseline and after the ablation. Intra-atrial and inter-atrial electromechanical delays, 
and PA-lateral were measured. All patients were scheduled for 24 h Holter recording at baseline 
and at 3, 6, 9 months follow-up. Venous samples were collected to measure CK-MB, Troponin-T 
(TnT), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels at baseline and 
24 h after ablation. Median follow up was 10 (8–12) months. Forty eight (80%) patients were in 
sinus rhythm during the follow up. In receiver operating curve (ROC) analysis, intraleft atrial 
electromechanical delay and PA-lateral achieve an area under the curve (AUC) 0.97 (p < 0.001) 
and 0.69 (p < 0.001) for the ability to predict AF recurrence. A cut-off value for baseline intraleft 
atrial electromechanical delay of 29.5 ms predicted AF recurrence with sensitivity of 85% and 
specifity of 98%. A cut-off value for PA-lateral of 125 ms predicted AF recurrence with sensitivity 
of 80% and specifity of 90%. In ROC analysis, age achieves an AUC 0.822 (p = 0.006) for the 
ability to predict AF recurrence. A cut-off value for age of 64 predicted AF recurrence with sen-
sitivity of 71% and specifity of 90%. Early recurrence of AF (HR = 60, 95% CI 18.61–417.86,  
p < 0.001) predicted also late recurrence of AF. 
Conclusions: The increase in AF recurrence by increased intraleft atrial electromechanical 
delay, PA-lateral and older age show the importance of substrate in AF mechanism. Early 
recurrence was the strongest predictor of late recurrence of AF; therefore, existence of blanking 
period for cryoballoon ablation should be questioned. (Cardiol J 2013; 20, 3: 294–303)
Key words: cryoballoon ablation, intraleft AEMD, early atrial fibrillation  
recurrence 
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Introduction
Atrial fibrillation (AF) is the most common 
cardiac arrhythmia. The treatment approach for 
AF includes either restoration and mainteinance of 
sinus rhythm or ensuring adequate ventricular rate 
control. Maintainance of sinus rhythm may be pro-
vided by anti-arrhythmic drugs (AADs) or catheter 
ablation. Catheter ablation of AF is recommended 
for patients with symptomatic paroxysmal atrial 
fibrillation (PAF) despite AADs [1]. Pulmonary 
vein isolation (PVI) has become a major curative 
measure of AF in drug resistant patients [2, 3]. 
Radiofrequency (RF) ablation is widely accepted as 
an effective treatment for PAF. Performing point-
-by-point ablation using RF energy is challenging. 
Cryoenergy by cryoballoon technique is an alterna-
tive to RF ablation. Balloon-based cryoenergy for 
PVI simplifies the reliable creation of a complete 
circumferential lesion around the pulmonary veins 
(PV) with only a  limited number of applications. 
Cryoballoon ablation is safe, and has a  similar 
success rate, when compared to RF ablation with 
comparable procedure and fluoroscopy times in 
patients suffering from PAF [4]. However, reported 
1 year success rates are limited to 60–74% [5–8]. 
Therefore, the aim of this study is to identify the 
predictors of success specifically in patients un-
dergoing cryoballoon ablation for PAF. 
Methods
Patients
Sixty one consecutive patients without struc-
tural heart disease with symptomatic PAF resistant 
to one or more AADs, who were referred for cathe-
ter ablation to Hacettepe University Hospital, were 
enrolled in this study. During transseptal puncture 
cardiac tamponade occurred in one patient and he 
was treated by percutaneous pericardiosynthesis.
The process was terminated and that patient was 
not included in the analysis. Residual 60 patients 
(36 males, mean age 54.6 ± 10.7) were followed 
and analyzed. European Heart Rhythm Associa-
tion (EHRA) symptom scores of all patients were 
recorded. Alcohol consumption of patients was 
inquired; patients were classified as nondrinkers, 
moderate drinkers (having up to 1 drink per day 
for women and up to 2 drinks per day for men) and 
heavy drinkers (more than moderate drinking) [9]. 
Before and 24 h after the ablation cardiac enzymes 
(CK-MB, troponin-T [TnT]) and inflammatory 
markers (erythrocyte sedimentation rate [ESR] 
and C-reactive protein [CRP]) were measured. 
Patients were followed with routine and symp-
tom-driven ambulatory monitoring at hospital. 
Follow-up was scheduled at 3, 6, 9, and 12 months 
following ablation. Patients resumed their oral 
anticoagulation and AAD, except amiodarone, fol-
lowing ablation for at least 3 months. If they had 
remained in sinus rhythm, their AADs would have 
been discontinued at the 3-month follow-up visit. 
Anticoagulation decision after 3 months was made 
according to CHA2DS2-VASc stroke risk score. 
Transesophageal echocardiography was per-
formed on all candidates to exclude the presence 
of thrombi. 
Recurrence was defined as any documented 
atrial tachyarrhythmia (AF or an organized atrial ta-
chyarrhythmia) lasting at least for 30 s. Recurrences 
that occurred at any time during the 3-month blanking 
period following ablation were classified as early, 
recurrences beyond the 3-month blanking period 
following the procedure were classified as late [3]. 
The exclusion criteria were as follows: (1) pa-
tients who had structural heart disease, moderate-
-severe valvuler disease, (2) ejection fraction (EF) 
< 55% (measured by transthoracic echocardio-
gram), (3) left atrial diameter > 50 mm, (4) patients 
who had hyperthyroidism, (5) contraindication to 
anticoagulation. 
All patients gave their written informed con-
sent prior to inclusion in the study. The study 
was approved by the local institutional ethics 
committee.
Electrocardiographic evaluation
Standard ECG were taken from all patients 
with sweeping rate of 25 mm/s and amplitude of 
1 mV/cm. P-wave dispersion (PWD), defined as the 
difference between Pmax and Pmin, was manually 
measured from 12-lead ECG during sinus rhythm 
by 2 independent and experienced investigators 
using magnifying lens and calipers [10, 11].
Transthorasic echocardiography
Transthorasic echocardiographic examination 
was performed on all subjects using a SystemFive 
(GE Vingmed Ultrasound, Horten, Norway) cardiac 
ultrasound scanner with 2.5–3.5 MHz transducers. 
Left atrial diameter and left ventricular end diasto-
lic diameter were measured in anatomical M-mode 
in a parasternal long axis view. Left ventricular 
(LV) EF was measured according to the modified 
Simpson’s method using apical 4- and 2-chamber 
views. Pericardial effusion was determined before 
the ablation and in the first day after the ablation. 
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Lead II electrocardiogram was recorded con-
tinuously. Pulsed wave tissue Doppler echocardio-
graphy was performed by transducer frequencies of 
3.5–4.0 MHz, adjusting the spectral pulsed Doppler 
signal filters up to a Nyquist limit of 15–20 cm/s, 
and using the minimal optimal gain. The monitor 
sweep speed was set at 50–100 mm/s to optimize 
the spectral display of myocardial velocities. In 
apical 4-chamber view, the pulsed Doppler sample 
volume was subsequently placed at the level of LV 
lateral mitral annulus, septal mitral annulus and 
right ventricular (RV) tricuspid annulus. Tissue 
Doppler pattern was characterized by a positive 
myocardial systolic wave (S) and 2 negative diasto-
lic waves; early (E) and atrial (A). Time intervals 
from the onset of P wave on the surface ECG to 
the beginning of A wave (PA) representing atrial 
electromechanical delay (AEMD) were obtained 
from lateral mitral annulus, septal mitral annulus 
and RV tricuspid annulus, and named as lateral 
PA, septal PA and RV PA respectively (Fig. 1). The 
timing of mechanical activation of each reference 
point, namely lateral mitral, septal mitral and RV 
tricuspid annuli, depends on the distances of these 
points to sinus node.The RV tricuspid annulus is 
the earliest, and lateral mitral annulus are the latest 
points to be activated by the impulse arising from 
the sinus node. Therefore, it is hypothesized that 
the difference between any 2 reference points re-
flects the mechanical delay between these 2 points. 
The difference between septal PA and RV PA was 
defined as intra-right AEMD (septal PA–RV PA), 
the difference between lateral PA and septal PA 
was defined as intraleft AEMD (lateral PA–septal 
PA), and the difference between lateral PA and 
RV PA (lateral PA–RV PA) was defined as inter-
-AEMD [12, 13]. Echocardiographic analysis was 
performed by the same echocardiographer in order 
to eliminate inter-observer variability. All patients 
were examined before the ablation.
Computerized tomography
All patients (61) were evaluated with contrast 
enhanced cardiac computed tomography (CT) 
angiography before the ablation. Multidetector 
row CT technology was used (Definition, Siemens 
Medical Solutions, Erlangen, Germany). ECG-re-
ferenced scans were performed after intravenous 
administration of contrast material. Because pul-
monary vein assessment was the primary clinical 
goal, 1.5-mm-thick images were reconstructed. 
Standard clinical workstation (Leonardo, Siemens) 
was used and advanced 3D off-line postprocessing 
was performed. The 3D CT dataset was reconstru-
cted to obtain standard cardiac views as used in 
echocardiography. We first reconstructed standard 
2- and 4-chamber views. Left atrium (LA) size was 
determined by manually tracing the LA borders in 
the 4-chamber view and using computer software 
that calculates the outlined area. The short-axis 
view was reconstructed as a plane perpendicular 
to the long axis of these 2 views at the level of 
the mid LA. In this short-axis view, the periatrial 
epicardial fat thickness was measured (in cm) as 
the shortest distance between the mid LA wall and 
3 anatomic landmarks: esophagus (E–LA), main 
pulmonary artery (LA–PA), and descending thora-
cic aorta (Ao–LA) (Fig. 2). These measurements 
were prospectively determined, based on prelimi-
nary reviews of representative CT scans before 
starting the study, which showed that the esopha-
gus, PA, and thoracic aorta were readily identifiable 
anatomic structures that could be used to measure 
LA epicardial fat [14]. 
Measurements were made using digital cali-
pers by a single investigator with an intraobserver 
reproducibility of 0.961 (95% confidence interval 
[CI] 0.912–0.986; intraclass correlation, same 
below) on measurements of LA area and 0.972 
(95% CI 0.932–0.998) on measurements of epi-
cardial fat. In a sample of 40 randomly selected 
patients, the interobserver reliability was 0.952 
(95% CI 0.920–0.971) on measurements of LA area 
and 0.975 (95% CI 0.948–0.992) on measurements 
of epicardial fat. 
Ablation procedure
PVI using the cryobal loon technique 
(ArcticFrontTM, Cryocath, Quebec, Canada) was 
performed as described before [7, 8, 15]. The 
28 mm balloon was used. With the deflated balloon 
Figure 1. Time interval from the onset of P wave on 
surface ECG to the beginning of A wave (PA).
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catheter inside the sheath, a guidewire was placed 
in one of the pulmonary vein (PV) branches. The 
balloon was then advanced towards the PV ostium 
and inflated. We aimed for at least 2 cryoballoon 
ablations on every targeted PV. Additional delivery 
of cryoenergy was applied after the guidewire was 
placed in different branches of the PV with early 
branching, which usually allowed for better contact 
of the balloon at different sites of the PV antrum. 
Application time was 240 to 400 s per freeze. If 
PV occlusion was not achieved by simply pushing 
the balloon against the PV ostium, additional 
techniques, previously described as “hockey stick 
technique” and “pull-down technique”, were per-
formed [6]. A 6-F decapolar catheter was advanced 
to the coronary sinus for anatomical guidance and 
pacing, it was also used to measure the intra-left 
atrial conduction time (ILCT). ILCT was measured 
as the difference between atrial electrograms in 
proximal and distal CS electrodes [16]. 
A multipolar catheter was placed in the su-
perior vena cava for phrenic nerve stimulation 
during ablation of the right-sided PVs. The PVs 
were checked for isolation 20 min after the last 
application in the same order as they had been 
frozen with a circular mapping catheter (LASSO, 
Biosense Webster, USA). 
Statistical analysis
All statistical analyses were performed using 
the Statistical Package for the Social Sciences 
(version 20.0, SPSS, Inc., Chicago, U.S.). Conti-
nuous variables are reported as mean±standard 
deviation (SD) or median, interquartile range 
(IQR). Categorical variables are presented as num-
ber (percentage) and were compared by means of 
the c2 test. Continuous variables were analyzed 
for a normal distribution using the Kolmogorov-
-Smirnov test and Shapiro-Wilk test. Comparison 
of continuous variables was performed using the 
Student’s t-test. For comparing nonparametric 
variables Mann-Whitney U test and Wilcoxon Rank 
Tests were used. Univariable and multivariable 
Cox proportional hazard analyses were performed 
to investigate predictors of AF recurrence after 
cryoballoon ablation. Age, gender, hypertension, 
coronary artery disease, alcohol consumption, 
AF duration, LA diameter, LA volume, EF, EHRA 
symptom score, pericardial effusion, biomarkers, 
p wave dispersion, ILCT, PA septal, PA lateral, 
PA tricuspit, intra-right AEMD, intra-left AEMD, 
inter AEMD, epicardial fat thickness, and early 
recurrence of AF were included in the univariable 
analyses. Variables with a p value < 0.05 in the 
univariate analysis were included into the multiva-
riate analysis. Multivariate analysis was performed 
using a backward stepwise conditional approach. 
Event-free survival was calculated by Kaplan-
-Meier analysis as the time from initial pulmonary 
vein isolation to the first documented AF episode. 
Receiver operating characteristics (ROC) curve 
analysis was performed to establish the parameters 
that can best predict the arial fibrillation recurrence 
and the best cut-off points for those parameters. 
Correlation was tested with Pearson correlation 
coefficient. P value less than 0.05 was considered 
statistically significant.
Results
We analyzed 60 patients (36 males) with mean 
age of 54.6 ± 10.7 and LA size of 3.74 ± 0.39 mm; 
EF of 66.00 ± 5.09; unsuccessful AAD number of 
1.36 ± 0.6; median EHRA score of 3. All patients 
had used at least 1 AAD and 16 (26%) of patients 
used amiodarone. Other AADs were propafenon, 
Figure 2. In this view, the thickness of the epicardial fat 
can be demonstrated between the LA and 3 anatomic 
landmarks: esophagus, main pulmonary artery, and de-
scending thoracic aorta; PA — main pulmonary artery; 
LA — left atrium; Ao — descending aorta; E — esopha-
gus; PA-LA — peri-atrial epicardial fat located between 
mid left atrium and pulmonary artery; E-LA — periatrial 
epicardial fat located between mid left atrium and esop-
hagus; Ao-LA — periatrial epicardial fat located be-
tween mid left atrium and descending aorta. Orientation 
cube: A — anterior; F — feet; L — left. 
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sotalal and dronaderone. Five (8.3%) patients had 
coronary artery disease and 23 (38.3%) patients 
had hypertension. Thirteen (21.6%) patients were 
moderate alcohol drinkers, others were nondrin-
kers, there were no heavy alcohol drinkers. Seven 
(11.6%) patients had previous radiofequency (RF) 
ablation procedure. Baseline clinical characteristics 
and echocardiographic parameters are shown in 
Tables 1 and 2. The procedural end-point of PV 
isolation was reached in all patients.
All biomarkes were in the normal range before 
the procedure and all of the biomarkers increased 
after the procedure (Table 3). 
Follow up
Patients were followed for a median of 10 
(8–12) months. Eighty percent of patients reached 
to 1 year follow up. Patients had an ECG recorded 
at each follow-up visit along with Holter monitoring 
(24 h) 3, 6, and 12 months following the ablation. 
AF recurred in the first 3 months in 10 patients 
(17%) and in 8 patients of those (80%) AF recurred 
after first 3 months. RF ablation was performed for 
2 patients and reconnection was seen in the left 
lower PV. Six patients were followed with AAD. 
Three of these patients experienced typical atrial 
flutter, 1 patient experienced LA tachycardia and 
other 6 had AF. Forty eight (80%) patients were in 
sinus rhytm during the follow up (Fig. 3). 
Factors related to late recurrence of AF
Univariate and multivariate Cox proportional 
hazard analyses were performed for predictors of 
late recurrence of AF. The clinical features of pa-
tients with and without late recurrence of AF are 
shown in Table 4. Significant univariate predictors 
of AF recurrence following ablation were: age 
(HR = 1.18, 95% CI 1.05–1.33, p = 0.006), EHRA 
symptom score (HR = 13.43, 95% CI 2.21–81.71, 
p = 0.005), intra-left AEMD (HR = 1.57, 95% CI 
1.16–2.12, p = 0.003), PA-lateral (HR = 1.12, 95% 
Table 1. Baseline clinical characteristics of pa-
tients.
Age (mean) 54.6 ± 10.7
Male 36 (60%)
Coronary artery disease 5 (8.3%)
Hypertension 23 (38.3%)
Alcohol consumption 13 (21.6%)
Previous AF ablation 7 (11.6%)
AF duration (months, median, IQR) 36 (24–96)
Amiodarone 16 (26.6%)
Antiarrhythmic drug 1.36 ± 0.6 
EHRA symptom score (median) 3
P wave dispersion [ms] 46.40 ± 8.2
Intra-left atrial conduction time [ms] 26 ± 8
AF — atrial fibrillation; EHRA — European Heart Rhythm Association
Table 2. Baseline echocardiographic parameters 
of patients.
Left atrium diameter [cm] 3.74 ± 0.39 
Left atrium volume [mL] 48 ± 3 
Ejection fraction [%] 66.00 ± 5.09
PA septal [ms] 106.28 ± 15.96
PA lateral [ms] 126.57 ± 26.6
PA tricuspit [ms] 88.64 ± 17.57
Intra-right AEMD [ms] 16.9 ± 9.2
Intra-left AEMD [ms] 24.43 ± 6.96
AEMD — atrial electromechanical delay
Table 3. Post-procedure biomarkers’ values.
Biomarker Post-prosedure Normal limits 
C-reactive protein median (min, max) 0.82 (0.01–4.07) mg/dL 0–0.8 mg/dL
Troponin-T median (min, max) 0.41 (0.01–1.16) ng/mL < 0.014 ng/mL
CK-MB median (min, max) 18.4 (2.69–56.88) ng/mL 0–4.94 ng/mL
Figure 3. Kaplan-Meier plot on event free survival to first 
ECG documented atrial fibrillation period postablation.
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CI 1.01–2.02 p = 0.006), PWD (HR = 1.36, 95% CI 
1.10–1.96, p < 0.003), ILCT (HR = 1.40, 95% CI 
1.18–2.02, p < 0.001) and early recurrence of AF 
(HR = 60, 95% CI 18.61–417.86, p < 0.001). We 
also looked at data and determined if a correlation 
existed between intra-left AEMD and ILCT and 
p wave dispersion. Intra-left AEMD and ILCT 
showed a moderate positive correlation (r = 0.694, 
p < 0.001), intra-left AEMD and p wave disper-
sion showed weak positive correlation (r = 0.482, 
p < 0.001) (Fig. 4).
AF duration prior to ablation, gender, coronary 
artery disease, hypertension, alcohol usage, LA 
diameter, LA volume, EF, biomarkers, epicardial 
fat, pericardial effusion were not related to late 
recurrence of AF.
Following multivariate analysis, significant 
predictors of AF recurrence were the same as the 
univariate analysis. 
ROC curve analysis of intra-left AEMD, PA 
lateral and age showed that they had AUC of 
0.973; 0.694 and 0.821 (ROC curves analysis, 
p < 0.001) (Fig. 5). The sensitivity of intra-left 
AEMD ³ 29.5 ms for predicting AF recurrence was 
85% with a specificity of 98%. The sensitivity of 
PA lateral ³ 125 ms for predicting AF recurrence 
was 80% with a specificity of 90%. The sensitivity 
of 64 years age for predicting AF recurrence was 
71% with a specificity of 90%. 
Discussion
In this study, we investigated the predictors 
of recurrence in patients undergoing cryoballoon 
ablation for paroxysmal AF. The main findings were 
as follows: clinical success in regard to the freedom 
from recurrent AF was 80%, early recurrence of 
AF was the most important predictor of late recur-
rence of AF, intra-left AEMD, PA lateral, EHRA 
symptom score and age predicted late recurrence 
of AF. Atrial fibrillation duration prior to ablation, 
gender, coronary artery disease, hypertension, 
alcohol consumption, LA diameter, LA volume, EF, 
biomarkers, epicardial fat, pericardial effusion did 
not predict late recurrence of AF. 
One year success of AF ablation in other stu-
dies was 60–70% [17, 18]. Eighty percent success 
of our study may be the result of normal LA dimen-
Table 4. Characteristics of patients with and without late recurrence of AF.
Variable Late recurrence of AF No recurrence P
Age 61.75 ± 9.91 52.80 ± 10.25 0.002
Gender (M/F) 29/19 7/5 0.98
Hypertension 6 17 0.41
Coronary artery disease 3 2 0.52
EHRA symptom score 4 3 0.001
Alcohol consumption 5/12 (41.66%) 8/48 (16.6%) 0.07
Intra-left AEMD [ms] 34.14 ± 9.45 23.09 ± 5.43 < 0.001
PA septal [ms] 107.32 ± 16.82 106 ± 14. 72 0.73
PA lateral [ms] 134.57 ± 16.66 120 ± 13.72 < 0.001
PA tricuspit [ms] 90.62 ± 16.62 86.72 ± 12.54 0.62
Intra-right AEMD [ms] 18.8 ± 4.72 14.92 ± 5.64 0.72
Inter AEMD [ms] 42.38 ± 14.04 38.64 ± 10.44 0.46
Early recurrence of AF 8/12 (66.7%) 2/46 (4.2%) < 0.001
PAF duration (median) [month] 60 36 0.35
LA diameter [cm] 3.75 ± 0.39 3.68 ± 0.39 0.55
LA volume [mL] 49 ± 3 46 ± 2 0.72
Ejection fraction [%] 65.50 ± 3.52 66.15 ± 5.45 0.63
E-LA [cm] 0.48 ± 0.07 0.46 ± 0.09 0.56
PA-LA [cm] 0.62 ± 0.16 0.68 ± 0.2 0.42
Ao-LA [cm] 0.39 ± 0.11 0.50±0.14 0.053
P wave dispersion [ms] 51.22 ± 6.12 42 ± 4.82 < 0.001
Intra-left atrial conduction time [ms] 36.22 ± 8.42 22.22 ± 5.23 < 0.001
AF — atrial fibrillation; LA — left atrium; EHRA — European Heart Rhythm Association; AEMD — atrial electromechanical delay,  
PA-LA — peri-atrial epicardial fat located between mid left atrium and pulmonary artery; E-LA — periatrial epicardial fat located between 
mid left atrium and esophagus; Ao-LA — periatrial epicardial fat located between mid left atrium and descending aorta
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sions, inclusion of only PAF patients, no structural 
heart disease, and single center study. 
Previous studies showed that postablation 
inflammation around PVs caused increase in inflam-
matory markers and cardiac enzymes [19, 20]. 
When cryoballoon ablation is performed, lesion 
formation occurs at the entire circumference of the 
balloon and that results in a long circumferential 
lesion. The higher rise of biomarkers indicates 
more myocardial injury. However, this did not 
translate into late ablation success in our study. 
These markers represent overall inflammation and 
injury, they don’t represent each PV separately. 
Therefore, higher rise may represent the sum of 
one transmural lesion and one superficial lesion.
AF ablation creates large lesions and this may 
play a role in effusion formation. Ten percent of 
our patients had pericardial effusion. Pericardial 
effusion may be a sign of lesion thickness. Peri-
cardial effusion and late recurrence of AF were 
not related (p > 0.05) in our study, it may be due 
to the fact that it is a nonspesific sign of injury 
as biomarkers. 
Batal et al. [14] demonstrated that increased 
posterior LA fat thickness was associated with 
AF burden independent of age, body mass index, 
or LA area. They tought that local inflammatory 
mediators produced by the periatrial epicardial fat 
in the LA posterior wall promoted the activation 
of ectopic foci in the PV ostia. In our study we 
could not find any relationship between periatrial 
adiposity and late recurrence of AF. 
Ethanol and its metabolite acetaldehyde have 
been shown to increase levels of circulating ca-
techolamines. Ethanol may also induce oxidative 
stress and release of plasma free fatty acids. These 
indirect effects of ethanol may be arrhythmogenic, 
particularly in individuals prone to AF such as 
patients with focal AF. A meta-analysis supported 
these pathophysiologic expression and showed that 
habitual heavy alcohol drinking was associated with 
an increased risk of AF [21]. 
Figure 5. Receiver operating characteristic curves for 
intra-left atrial electromechanical delay (AEMD) (AUC: 
0.97, 95% CI 0.93–1.00, p < 0.001), PA-lateral (AUC: 
0.69, 95% CI 0.45–0.93, p < 0.001) and age (0.87, 95% CI 
0.74–1.00, p < 0.006).
Figure 4. Scatter plot graphs showing the correlations 
between intra-left atrial electromechanical delay (AEMD) 
and intra-left atrial conduction time (ILCT) and p wave 
dispersion.
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In our study there was no relationship between 
alcohol intake and late recurrence of AF. It may 
be related to our patient population, because all of 
our patients were moderate alcohol drinkers and 
nondrinkers. 
In our study we could not find any stastical 
significant relationship between late recurrence 
of AF and LA diameter, LA volume and EF, it 
may be related to their normal values. Perhaps 
LA anatomical remodelling was less in our group. 
There was no relationship with AF duration also, 
it may be because it doesn’t demonstrate the AF 
frequency and AF episode duration, so it doesn’t 
reflect atrial remodeling.
High EHRA symptom score was related to 
late recurrence of AF, perhaps it is because these 
patients have more symptomatic PAF episodes 
than the others. 
Age 
It was shown that age was a strong predictor 
of AF recurrence in patients with maze procedure 
and RF AF ablation [22–25]. Ageing leads to inter-
stitial fibrosis and more extensive LA remodeling; 
therefore it increases the likelihood of additional 
AF triggers, which may predispose to recurrent 
AF after limited ablation. By ageing scar in the LA 
increases, the presence of LA scar is more impor-
tant than enlargement in predicting AF recurrence 
[26]. In our study, as in the previous studies, age 
was predictor of late recurrence of AF and when 
the cut-off point of age is 64 the sensitivity for 
predicting AF recurrence was 71% with a specifity 
of 90%. This result reminds about the importance 
of the substrate in spite of normal LA dimensions.
Intra-left AEMD, P wave dispersion, ILCT, 
PA lateral 
Development of AF requires a “trigger” and 
an anatomic or functional substrate capable of both 
initiation and perpetuation of AF. Atrial remodeling 
constitutes for substrate. Atrial remodeling deve-
lops in 3 levels; electrical, cellular and anatomical. 
The electrical remodeling process contributes to 
the increasing stability of AF during the first days 
after its onset. Electrical remodeling in AF is de-
scribed as shortening of atrial effective refractory 
period, discordance of atrial effective refractory 
period with heart rate and increase in intra-atrial 
conduction time. Short refractory period and 
delayed conduction may increase the number of 
daughter wavelets. Relation between Inter-atrial 
and intra-atrial conduction block and AF was shown 
in previous studies [27, 28]. 
In our study intra-left AEMD, P wave disper-
sion, ILCT and PA lateral were shown as predictors 
of late recurrence of AF (p < 0.001). There was 
moderate correlation between intra-left AEMD 
and ILCT, and weak correlation between intra-left 
AEMD and p wave dispersion. These results are 
similar to the results of Deniz et al. [29] study. 
Therefore, intra-left AEMD can be used as indictor 
of atrial conduction time for prediction of sinus 
rhythm maintenance. 
Deniz et al. [30] demonstrated an increase in 
intra-left atrial mechanical delay in PAF patients 
and this delay was an independent risk factor for 
PAF. den Uijl et al. [31] demonstrated relationship 
between PA lateral and late recurrence of AF. In 
our study the area under the ROC curve (index of 
discrimination) for PA lateral was 0.69 (p < 0.001), 
indicating a low discriminative power. The intra-
-left AEMD demonstrated a  higher degree of 
discrimination than PA lateral with an area under 
the ROC curve of 0.97 (p < 0.001). 
All of these show importance of LA remodeling 
in AF recurrence with normal LA dimensions. 
Early recurrence of AF (ERAF)
In previous RF ablation studies early recurren-
ce was observed in 33.8–54% of patients [32–35], 
so early recurrence was traditionally seen as 
a benign process not affecting long term results. 
Then, a lot of studies showed that ERAF was an 
important risk factor for late recurrence of AF 
[33, 35–40]. The possible causes of ERAF are: 
(1) transient stimulatory effect of acute inflam-
matory response following the histopathologic 
tissue damage that resulted from RF energy; 
(2) reconnection of electrical conduction between 
the LA and PVs and/or resumption of electrical 
activity in pre-ablation lines; (3) non-PV foci trig-
gering AF, and (4) transient imbalance of autonomic 
nervous system [35].
In our study, ERAF (HR = 60, 95% CI 18.61– 
–417.86, p < 0.001) was the most important pre-
dictor of late recurrence of AF. ERAF was seen 
in 10 patients (17%). ERAF percent was lower 
in our study, it may be due to the choice of using 
cryoenergy in our study. Therefore, there was 
a smaller inflammation reaction, smaller triggering 
effect and all of our patients were PAF patients with 
normal LA dimensions, so that is why there were less 
triggers out of PVs. Usually, in RF ablation studies, 
50% of patients with ERAF get better [32, 33, 39, 41], 
but in our study there had been no improvement in 
8 (80%) patients with ERAF and in these patients 
late recurrence was seen. This may be because of 
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the fact that we used cryoenergy and others used 
RF energy. RF energy causes larger inflammation 
and this may trigger early AF but cryoenergy 
causes less inflammation so it has less triggering 
effect. When there is an early recurrence with 
cryoenergy it is probably because of reconnection. 
There is a  blanking period description for RF 
ablation but we advise to revise the existence of 
blanking period for cryoballoon ablation. 
Limitations of the study
A relatively small number of patients is the 
main limitation of our study. The follow up period 
is not long enough (1 year). Some asymptomatic 
recurrence may be undetected without the use of 
long-term recording. Substrate, as a predictor of 
recurrence, could have been visualized better by 
magnetic resonance imaging. 
Conclusions 
Our study is the first study showing the rela-
tion between intra-left AEMD and late recurrence 
of AF. It is a better predictor than PA lateral. Age is 
an important factor for late recurrence of AF. These 
three parameters indicate the importance of atrial 
remodeling and atrial substrate. Extended ablation 
techniques may be used for such patients. Early 
recurrence of AF is the most important predictor 
of late recurrence of AF in cryoballoon ablation 
patients. Existence of blanking period should be 
reevaluated for cryoballoon ablation.
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